Aurobindo said its purchase of Sandoz’ US business, which would make it the second-biggest player in the country’s prescription market, should be completed “very soon” as it reported a nearly 40% leap in net profit that beat market estimates and sent its shares soaring.
Aurobindo Expects Sandoz Completion ‘Very Soon’
Aurobindo Pharma says its billion-dollar purchase of Sandoz’s US business is on track for completion “very soon” as it announced net first-quarter net profit that rocketed by nearly 40%, powered by strong US sales.
More from Deals
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
More from Business
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
• By
Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.